• <em>PNPLA6</em> Disorders
• <em>PNPLA6</em> disorders: what's in a name?
• A case of Oliver-McFarlane syndrome caused by PNPLA6 gene mutation
• A new PNPLA6 mutation presenting as Oliver McFarlane syndrome
• Coexistence of Retinitis Pigmentosa and Ataxia in Patients with PHARC, PCARP, and Oliver-McFarlane Syndromes
• COVID-19 in patients undergoing long-term dialysis in Ontario
• Delayed Induction of Human NTE (PNPLA6) Rescues Neurodegeneration and Mobility Defects of Drosophila swiss cheese (sws) Mutants
• Different Cerebellar Ataxia Phenotypes Associated with Mutations of the PNPLA6 Gene in Brazilian Patients with Recessive Ataxias
• Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
• Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
• Eyelash Trichomegaly: A Rare Presenting Feature of Systemic Lupus Erythematosus
• Eyelash trichomegaly: a systematic review of acquired and congenital aetiologies of lengthened lashes
• Eyelash Trichomegaly: Unusual Feature Associated with Systemic Lupus Erythematosus Patient
• Identification of Oliver-McFarlane syndrome caused by novel compound heterozygous variants of PNPLA6
• Infection Control Practices in In-Center Hemodialysis Units During Wave 1 of the COVID-19 Pandemic in Ontario, Canada: Research Letter
• Mutations in PNPLA6 are linked to photoreceptor degeneration and various forms of childhood blindness
• Neuropathy target esterase activity defines phenotypes among PNPLA6 disorders
• Neuropathy target esterase impairments cause Oliver-McFarlane and Laurence-Moon syndromes
• Novel variants in PNPLA6 causing syndromic retinal dystrophy
• Oliver McFarlane syndrome and choroidal neovascularisation: a case report
• Oliver McFarlane syndrome: two new cases and a review of the literature
• Province-Wide Prevalence Testing for SARS-CoV-2 of In-Center Hemodialysis Patients and Staff in Ontario, Canada: A Cross-Sectional Study
• Retinitis Pigmentosa in Oliver McFarlane Syndrome